Resistant hypertension

Kardiol Pol. 2018;76(7):1031-1042. doi: 10.5603/KP.a2018.0129. Epub 2018 Jun 15.


The publication of the first non-randomised proof-of-concept trial of renal denervation as a treatment modality in treatment- -resistant hypertension set the stage for a search for novel devices with the expectation that technology would reduce the burden of hypertension by reducing or eliminating the costly and lifelong use of blood pressure-lowering medications. As we demonstrate in this review, this idea was so attractive to manufacturers and invasive cardiologists and radiologists that they overlooked decades of careful pathophysiological research in a disease that remains enigmatic but is still a major cause of cardio-vascular mortality worldwide. To make our point, we first reviewed the prevalence and risks associated with treatment-resistant hypertension. Next, we highlighted the key points required for the diagnosis of treatment-resistant hypertension, including the recording of ambulatory blood pressure and the assessment of adherence to medication. Finally, we summarised new insights in the management of treatment-resistant hypertension by medication and devices as well as in future research. Throughout our review, we focused on new evidence that had become available since 2013. Our conclusion is that optimising medical treatment based on simple algorithms remains the state of the art in treatment-resistant hypertension.

Keywords: baroreflex; pharmacology; renal denervation; resistant hypertension; sympathetic nervous system.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Blood Pressure Monitoring, Ambulatory
  • Denervation / methods*
  • Humans
  • Hypertension / diagnosis
  • Hypertension / epidemiology
  • Hypertension / surgery*
  • Hypertension, Renal / diagnosis
  • Hypertension, Renal / epidemiology
  • Hypertension, Renal / surgery
  • Kidney / innervation*
  • Prevalence
  • Treatment Outcome